Bioequivalence assessment of two formulations of ibuprofen

Drug Design, Development and Therapy

Volumn 5, Issue , 2011, Pages 427-433

  Al Talla, Zeyad A ^a   Akrawi, Sabah H ^b   Tolley, Luke T ^c   Sioud, Salim H ^a   Zaater, Mohammed F ^d   Emwas, Abdul Hamid M ^a  

^a KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Saudi Arabia)

^b AL AIN UNIVERSITY   (United Arab Emirates)

^c SOUTHERN ILLINOIS UNIVERSITY   (United States)

^d JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

Author keywords

Bioequivalence study; Ibuprofen; Pharmacokinetics

Indexed keywords

DOLORAZ; IBUPROFEN; INDOMETACIN; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; FREEZE THAWING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INTERMETHOD COMPARISON; MALE; NORMAL HUMAN; OUTCOME ASSESSMENT; PLASMA CONCENTRATION-TIME CURVE; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRAVIOLET RADIATION;

ADULT; AREA UNDER CURVE; CALIBRATION; CROSS-OVER STUDIES; DRUG STABILITY; HUMANS; IBUPROFEN; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 84859115784     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S24504     Document Type: Article

References (30)

1. Chen ML, Shah V, Patnaik R, et al. Bioavailability and bioequivalence: an FDA regulatory overview. Pharm Res. 2001;18:1645-1650.
2. Lee JY, Kim BC, Park SG. Average bioequivalence for two-sequence two-period crossover design with incomplete data. J Biopharm Stats. 2005;15:857-867.
3. Rani S, Pargal A. Bioequivalence: An overview of statistical concepts. Indian J Pharmacol. 2004;36:209-216.
4. Al-Talla ZA, Akrawi SH, Emwas AHM. Solid state NMR and bioequivalence comparison of the pharmacokinetic parameters of two formulations of clindamycin. Int J Clin Pharmacol Ther. 2011;49:469-476.
5. US Food and Drug Administration. Guidance for industry bioavailability and bioequivalence studies for orally administered drug products. In: US Department of Health and Human Services, Center for Drug Evaluation and Research, editors. Rockville, MD: US Food and Drug Administration; 2003.
6. Lee E, Williams K, Day R, Graham G, Champion D. Stereoselective disposition of ibuprofen enantiomers in man. Br J Clin Pharmacol. 2004;58:S759-S764.
7. Evans AM, Nation RL, Sansom LN, Bochner F, Somogyi AA. Stereoselective plasma protein binding of ibuprofen enantiomers. Eur J Clin Pharmacol. 1989;36:283-290.
8. Brunton L, Chabner B, Knollman B. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York, NY: McGraw-Hill; 2010.
9. Hersh E, Moore P, Ross G. Over-the-counter analgesics and antipyretics: a critical assessment. Clin Ther. 2000;22:500-548.
10. Department of Health. The British Pharmacopoeia. 99th ed. London, UK: Stationery Office Books; 1999.
11. Brunton L, Lazo J, Parker K. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York, NY: McGraw Hill; 2005.
12. Jorgensen B, Friis GJ, Gottrup F. Pain and quality of life for patients with venous leg ulcers: proof of concept of the efficacy of Biatain (R)-Ibu, a new pain reducing wound dressing. Wound Repair Regen. 2006;14:233-239.
13. Rasenack N, Müller B. Properties of ibuprofen crystallized under various conditions: A comparative study. Drug Dev Ind Pharm. 2002;28:1077-1089.
14. Southworth S, Peters J, Rock A, Pavliv L. A multicenter, randomized, double-blind, placebo-controlled trial of intravenous ibuprofen 400 and 800 mg every 6 hours in the management of postoperative pain. Clin Ther. 2009;31:1922-1935.
15. Dong YL, Fleming R, Yan TZ, Herndon DN, Waymack JP. Effect of ibuprofen on the inflammatory response to surgical wounds. J Trauma. 1993;35:340.
16. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A. 1993;90:11693.
17. Vane J. The mechanism of action of anti-inflammatory drugs. Int J Clin Pract. 2003;2:2.
18. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 2001;15:2057.
19. Heyman E, Morag I, Batash D, Keidar R, Baram S, Berkovitch M. Closure of patent ductus arteriosus with oral ibuprofen suspension in premature newborns: a pilot study. Neoreviews. 2003;11:e354.
20. Olive G. Analgesic/antipyretic treatment: ibuprofen or acetaminophen? An update. Therapie. 2006;61:151-160. French.
21. Antal E, Wright C, Brown B, Albert K, Aman L, Levin N. The influence of hemodialysis on the pharmacokinetics of ibuprofen and its major metabolites. J Clin Pharmacol. 1986;26:184.
22. Tripathi KD. Essentials of Medical Pharmacology. 5th ed. New Delhi, India: Jaypee Brothers Medical Publishers; 2004.
23. Gallo J, Gall E, Gillespie W, Albert K, Perrier D. Ibuprofen kinetics in plasma and synovial fluid of arthritic patients. J Clin Pharmacol. 1986;26:65.
24. US Food and Drug Administration. Guidance for Industry Statistical Approaches to Establishing Bioequivalence. In: US Department of Health and Human Services, Center for Drug Evaluation and Research, editors. Rockville, MD: US Food and Drug Administration; 2001.
25. World Medical Association. WMA Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects. 53rd ed. Washington, DC: World Medical Association; 2002.
26. Haikala VE, Heimonen IK, Vuorela HJ. Determination of ibuprofen in ointments by reversed-phase liquid-chromatography. J Pharm Sci. 1991;80:456-458.
27. Lalande M, Wilson DL, McGilveray IJ. Rapid high-performance liquid-chromatographic determination of ibuprofen in human-plasma. J Chromatogr. 1986;377:410-414.
28. Sochor J, Klimes J, Zahradnícek M, Sedlácek J. High-performance liquid chromatographic assay for ibuprofen in whole blood using solidphase extraction. J Chromatogr B Biomed Appl. 1994;654:282-286.
29. Dadgar D, Burnett PE, Choc MG, Gallicano K, Hooper JW. Application issues in bioanalytical method validation, sample analysis and data reporting. J Pharm Biomed Anal. 1995;13:89-97.
30. Walker R, Edwards C. Clinical Pharmacy and Therapeutics. Edinburgh, UK: Churchill Livingstone; 2003.